Building breakthroughs: Gilead invests in U.S. innovation
Gilead's $32B U.S. investment is fueling American science — and innovation. At Gilead, we strive to create a healthier world for all people.
Gilead invests in world-class science and is pursuing innovation across the therapeutic areas of virology, oncology and inflammation.
Gilead is investing $32 billion in the U.S. through 2030 to expand research, manufacturing and workforce infrastructure as part of a broader global strategy to deliver scientific breakthroughs where they can have the greatest impact.
The idea: Biopharmaceutical innovation can't happen without infrastructure. Gilead's expansion strategy helps ensure transformative medicines are discovered and delivered at home — while reinforcing the global pipeline that supports patients around the world.
"Our U.S. investment strategy reflects a simple belief: that the future of medicine should be built here," said Daniel O'Day, Chairman and CEO of Gilead Sciences. "By strengthening our American footprint as part of a global innovation engine, we're helping ensure patients everywhere benefit from our world-class therapies."
The strategy: Gilead's U.S. investment includes:
Investing in AI-enabled labs and advanced manufacturing sites.
Creating over 3,000 direct and supported jobs.
Expanding capacity for personalized therapies and large-scale production.
These efforts are designed to speed access to innovation, build supply chain resilience and redefine what's possible in medicine.
Key numbers:
98% of Gilead's R&D infrastructure is U.S.-based.
80%+ of profits are reinvested in the U.S.
$43B in projected U.S. economic impact.
Investing in our promise
Since 2017, Gilead has added more than 16,000 high-quality U.S. jobs, with over 70% of domestic employees focused on R&D. New investments are fueling advanced treatments in virology, inflammation and cancer.
At Gilead, every investment begins with people and ends with purpose. Our commitment to expanding U.S. infrastructure goes beyond facilities — it's about empowering communities and strengthening public health for the long term.
Engineering a new era of American innovation
The details:
Gilead is harnessing AI and automation to transform how medicines are discovered, manufactured, and delivered — faster, smarter and more safely.
Next-generation facilities in California will be equipped with predictive analytics, digital monitoring and autonomous robotics.
Designed in collaboration with Bay Area tech startups, these facilities set a new standard for biopharma infrastructure and speed — from groundbreaking to completion in under two years.
With more than $5 billion invested in facilities that map the flow of scientific innovation — from research to clinical manufacturing — Gilead's campuses embody the speed and agility of our discoveries.
Building resilience through science
Plus, plus, plus: During COVID-19, Gilead's U.S.-anchored supply chain ensured uninterrupted global access to essential treatments.
With the majority of our workforce and intellectual property based in the U.S. — and a global footprint spanning 70 sites across 38 countries — they're building a system that can adapt, shift and scale in real time. Strategic redundancy, flexible manufacturing and proven partnerships make our network a cornerstone of health security.
A global commitment, rooted at home
Worth a mention: While expanding its U.S. footprint, Gilead continues to invest in research, manufacturing and partnerships abroad. A globally integrated model ensures patients everywhere benefit from discoveries made at home.
Whether scaling a COVID-19 antiviral across continents or sourcing ingredients for personalized therapies, Gilead's global operations balance efficiency with equity — and keep patients at the center of everything they do.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
20 minutes ago
FDA requires updated warning about rare heart risk with COVID shots
WASHINGTON -- WASHINGTON (AP) — The Food and Drug Administration said Wednesday it has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men. Myocarditis, a type of heart inflammation that is usually mild, emerged as a complication after the first shots became widely available in 2021. Prescribing information from both Pfizer and Moderna already advises doctors about the issue. In April, the FDA sent letters to both drugmakers asking them to update and expand the warnings to add more detail about the problem and to cover a larger group of patients. While the FDA can mandate label changes, the process is often more of a negotiation with companies. Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old. The label also notes that the problem has been most common among males ages 12 to 24. The previous label said the problem mostly occurs in 12- to 17-year-olds. The FDA's labeling change appears to conflict with some prior findings of scientists elsewhere in the U.S. government. The Centers for Disease Control and Prevention previously concluded there was no increased risk of myocarditis detected in government vaccine injury databases for COVID-19 shots dating back to 2022. Officials also noted that cases tend to resolve quickly and are less severe than those associated with COVID-19 infection itself, which can also cause myocarditis. The FDA announcement came as new vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. met to debate the continuing use of COVID-19 vaccines for key groups, including pregnant women. It's the first meeting of the CDC advisory panel since Kennedy abruptly dismissed all 17 members of the group, naming a new panel that includes several members with a history of anti-vaccine statements. The FDA's label update is the latest step by officials working under Kennedy to restrict or undercut use of vaccines. FDA Commissioner Marty Makary and a top deputy recently restricted annual COVID-19 shots to seniors and other Americans at higher risk from the virus. They've also suggested seasonal tweaks to match the latest circulating virus strains are new products that require extra testing. Outside experts said the new warning is the wrong approach. 'They are right to suggest that we need to consider myocarditis risks associated with the vaccine, but what they propose is exactly the wrong solution,' said Dr. Robert Morris, a public health specialist at the University of Washington. 'We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk.' Makary and several other FDA officials gained prominence during the pandemic by suggesting the federal government exaggerated the benefits of COVID-19 boosters and downplayed serious side effects, including myocarditis. Before joining the government, Makary and two of his current FDA deputies wrote a 2022 paper that said mandating booster shots in young people would cause more vaccine-related injuries than prevented hospitalizations from COVID-19 infections. The conclusion contradicted that of many leading vaccine and public health experts at the time, including at the CDC. ___
Yahoo
25 minutes ago
- Yahoo
Gemini, ChatGPT may lose the AI war to deep-pocketed rival
Gemini, ChatGPT may lose the AI war to deep-pocketed rival originally appeared on TheStreet. Gemini, ChatGPT may lose the AI war to deep-pocketed rivals Markets have been jittery this year, and it all goes back to a single seismic moment in January. 💵💰💰💵 From ChatGPT to Gemini, AI sparked a massive stock market boom, with tech stocks soaring and early adopters laughing their way to the bank. Billions in market value have been added, thanks to a sustained long-term tailwind in AI. Many in the U.S. saw AI as a closed club run by a few gatekeeper tech giants. Earlier this year, in January, the 'DeepSeek' moment cracked that lock wide open, triggering one of the largest slides in tech stock history. Ever since, Mr. Market's been on edge, and now, with what dropped yesterday, it's looking like another shockwave could be on the way. DeepSeek burst onto the scene this year, shaking things up in Hangzhou-based startup, barely a year old, dropped its R1 chatbot, leaving experts in disbelief. The chatbot boasted an open-weight model with a training cost of just $6 million, way below the eye-watering budgets of its American peers. Its launch set off a brutal tech stock sell-off, one of the biggest we've seen in a long time. DeepSeek's launch on January 27 led the Nasdaq to a concerning 3.1% drop, while the S&P 500 slid almost 2%. Investors freaked out over the remarkably cheap, open-source AI proposition. In premarket trading that morning, Nvidia stock sank 13%, erasing north of $500 billion in market cap at the open. Moreover, the broader 'Magnificent 7' group, including the likes of Alphabet, Amazon, Apple, Meta, Microsoft, Nvidia, and Tesla, lost a combined $1 trillion in market cap. Right after DeepSeek dropped R1, it took off fast. The app shot to No. 1 on Apple's U.S. App Store, bumping ChatGPT, while topping charts in 50+ countries. By late May, the Chinese AI powerhouse was already back with a major upgrade. The new R1-0528 dropped on Hugging Face, packed new system prompts, function-calling, all while cutting hallucinations by roughly 50% and doubling the chain-of-thought window. They even rolled out a lightweight version on a single GPU, making advanced AI more DIY-friendly. Behind the scenes, OpenAI launched a probe into whether DeepSeek had scraped ChatGPT's data to train its model, adding more fuel to the AI wars. President Trump jumped on the moment, calling it a 'wake-up call' for U.S. tech to get serious about AI. Meanwhile, Apple's Tim Cook visited Beijing and praised DeepSeek's models, calling them 'excellent'. All said, DeepSeek isn't just holding strong, it's dominating. More on Tech and AI: Tesla's robotaxi rollout runs into trouble Struggling EV semiconductor company files for bankruptcy Struggling EV semiconductor company files for bankruptcy It snagged an estimated 89.3% of China's AI chatbot market, cementing its lead as the go-to chatbot for hundreds of millions across the mainland. China is gearing up for what's likely to be a tidal wave of AI innovation. According to Zhu Min, former deputy governor of the People's Bank of China, we could see over 100 'DeepSeek-like' breakthroughs over the next 18 the China Development Forum in Tianjin, Zhu predicts the momentum in homegrown AI platforms will 'fundamentally change the nature and the tech makeup of the entire Chinese economy.' DeepSeek has already rattled global markets this year and has the undivided attention of China's power hitters. State planners and VC firms are all in, pouring a ton of money on homegrown AI ventures and big-name sectors. Across the Pacific, U.S. officials are watching closely, eyeing export rules and IP protections as Beijing looks to solidify its AI positioning. DeepSeek is gearing up to release its much-talked-about R2 model. The big question is whether it can keep the momentum on both the hardware and software fronts. If it can, analysts say we could see a serious shift in global tech power by ChatGPT may lose the AI war to deep-pocketed rival first appeared on TheStreet on Jun 25, 2025 This story was originally reported by TheStreet on Jun 25, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
FDA requires updated warning about rare heart risk with COVID shots
WASHINGTON (AP) — The Food and Drug Administration said Wednesday it has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men. Myocarditis, a type of heart inflammation that is usually mild, emerged as a complication after the first shots became widely available in 2021. Prescribing information from both Pfizer and Moderna already advises doctors about the issue. In April, the FDA sent letters to both drugmakers asking them to update and expand the warnings to add more detail about the problem and to cover a larger group of patients. While the FDA can mandate label changes, the process is often more of a negotiation with companies. Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old. The label also notes that the problem has been most common among males ages 12 to 24. The previous label said the problem mostly occurs in 12- to 17-year-olds. The FDA's labeling change appears to conflict with some prior findings of scientists elsewhere in the U.S. government. The Centers for Disease Control and Prevention previously concluded there was no increased risk of myocarditis detected in government vaccine injury databases for COVID-19 shots dating back to 2022. Officials also noted that cases tend to resolve quickly and are less severe than those associated with COVID-19 infection itself, which can also cause myocarditis. The FDA announcement came as new vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. met to debate the continuing use of COVID-19 vaccines for key groups, including pregnant women. It's the first meeting of the CDC advisory panel since Kennedy abruptly dismissed all 17 members of the group, naming a new panel that includes several members with a history of anti-vaccine statements. The FDA's label update is the latest step by officials working under Kennedy to restrict or undercut use of vaccines. FDA Commissioner Marty Makary and a top deputy recently restricted annual COVID-19 shots to seniors and other Americans at higher risk from the virus. They've also suggested seasonal tweaks to match the latest circulating virus strains are new products that require extra testing. Outside experts said the new warning is the wrong approach. 'They are right to suggest that we need to consider myocarditis risks associated with the vaccine, but what they propose is exactly the wrong solution,' said Dr. Robert Morris, a public health specialist at the University of Washington. 'We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk.' Makary and several other FDA officials gained prominence during the pandemic by suggesting the federal government exaggerated the benefits of COVID-19 boosters and downplayed serious side effects, including myocarditis. Before joining the government, Makary and two of his current FDA deputies wrote a 2022 paper that said mandating booster shots in young people would cause more vaccine-related injuries than prevented hospitalizations from COVID-19 infections. The conclusion contradicted that of many leading vaccine and public health experts at the time, including at the CDC. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
